| Estimated Vaccination Coverage*,† among Adolescents Aged 13-17 Years§, by Race/ethnicity¶ for Selected Vaccines -- National Immunization Survey-Teen, United States, 2009 |
| Vaccines | White only, non-Hispanic % (95% CI) | Black only, non-Hispanic % (95% CI) | Hispanic % (95% CI) | American Indian or Alaska Native only, non-Hispanic % (95% CI) | Asian only, non-Hispanic % (95% CI) | ||
|---|---|---|---|---|---|---|---|
| >2 MMR** | 90.2 (89.3-91.1) | 86.3 (83.6-88.5) | 87.6 (84.9-89.9) | 90.4 (84.1-94.3) | 92.9 (88.5-95.8) | ||
| > 3 HepB†† | 90.2 (89.4-91.0) | 88.9 (86.7-90.8) | 90.0 (87.7-91.9) | 89.7 (83.2-93.9) | 89.5 (83.3-93.6) | ||
| Varicella | |||||||
| History of varicella disease§§ | 55.0 (53.5-56.4) | 49.0 (45.6-52.4) | 50.1 (46.3-53.9) | 52.3 (42.2-62.3) | 40.2 (31.7-49.4) | ||
| Among adolescents without history of disease: | |||||||
| >1 dose vaccine | 88.5 (87.0-89.8) | 82.4 (78.7-85.7) | 85.5 (81.1-89.0) | 87.9 (76.4-94.2) | 88.1 (79.9-93.2) | ||
| >2 dose vaccine | 48.8 (46.5-51.2) | 43.9 (39.2-48.6) | 49.7 (44.0-55.5) | 41.0 (26.6-57.1) | 54.2 (41.9-66.0) | ||
| History of disease or received =2 doses varicella vaccination¶¶ | 77.0 (75.7-78.2) | 71.3 (68.2-74.3) | 74.9 (71.4-78.1) | 71.9 (60.3-81.1) | 72.6 (63.7-80.1) | ||
| Td or Tdap since age 10 years*** | |||||||
| >1 dose Td or Tdap | 76.5 (75.4-77.7) | 72.5 (69.4-75.5) | 76.7 (73.2-79.9) | 78.0 (66.8-86.2) | 84.5 (77.1-89.8) | ||
| >1 dose Tdap | 55.8 (54.3-57.2) | 52.7 (49.3-56.1) | 55.6 (51.8-59.4) | 59.3 (48.8-69.1) | 64.3 (55.5-72.3) | ||
| MenACWY 1 dose††† | 53.1 (51.7-54.5) | 53.0 (49.6-56.4) | 55.9 (52.0-59.7) | 46.9 (37.3-56.8) | 58.8 (49.6-67.4) | ||
| HPV§§§ | |||||||
| >1 dose | 43.9 (41.8-46.1) | 44.6 (39.9-49.5) | 45.5 (40.3-50.8) | 52.3 (39.0-65.2) | 41.5 (29.5-54.5) | ||
| >3 doses | 29.1 (27.3-31.0) | 23.1 (19.1-27.6) | 23.4 (19.7-27.6) | 29.6 (20.1-41.4) | 22.1 (14.7-31.8) |
| * Estimate presented as point estimate (%) ± 95% confidence interval (CI). Estimate=NA (Not Available) if the unweighted sample size for the denominator | ||||||||||||
| was <30 or (CI half width)/Estimate > 0.6. | ||||||||||||
| † Estimates with confidence intervals >20 may not be reliable. | ||||||||||||
| § Adolescents in the 2009 NIS-Teen were born during January 1991-February 1997. | ||||||||||||
| Vaccination coverage estimates include only adolescents who had adequately complete provider-reported immunization records. | ||||||||||||
| National estimates do not include adolescents living in the U.S. Virgin Islands (i.e., St. Croix, St. Thomas, St. John, and Water Island) (n=333). | ||||||||||||
| ¶ Reported by respondent. Adolescents of Hispanic ethnicity may be of any race. | ||||||||||||
| Native Hawaiian or other Pacific Islanders and persons of multiple races were not included because of small sample sizes | ||||||||||||
| ** > 2 doses of measles-mumps-rubella vaccine. | ||||||||||||
| †† >3 doses of hepatitis B vaccine. | ||||||||||||
| §§By parent/guardian report or provider records. | ||||||||||||
| ¶¶ Prior tables reported "history of disease or received =1 dose varicella vaccination." We now report "history of disease or received =2 doses varicella vaccination" | ||||||||||||
| to follow current Advisory Committee of Immunization Practices guidelines for adequate protection against varicella infection. | ||||||||||||
| *** > 1 dose of tetanus toxoid-diphtheria vaccine (Td) or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years. | ||||||||||||
| ††† >1 meningococcal conjugate vaccine or meningococcal -unknown type vaccine. | ||||||||||||
| §§§ >1 human papillomavirus vaccine, either quadrivalent or bivalent. Percentages reported among females only. | ||||||||||||
| tab15_race_nat | ||||||||||